Dr. Jarle Bruun’s research profiled in the 2016 National report from the Regional Health Authorities
The report highlights clinically relevant research, and projects ongoing in the K.G. Jebsen Colorectal Cancer Research Centre were selected from the South-Eastern Norway Regional Health Authority. Specifically, Dr. Jarle Bruun's paper identifying the gene Regulator of Chromosome Condensation 2 (RCC2) as functionally important in colorectal cancer, and furthermore that changes of RCC2 at the DNA and protein level can identify clinically distinct subgroups of patients with inferior survival.
Epigenetic markers stratify colorectal cancer patients within a genetically defined poor prognostic patient group
Vedeld and co-workers show that the CpG Island Methylator Phenotype (CIMP) carry prognostic value across stages. Patients with microsatellite stable tumors with BRAF V600E mutations, defining a poor prognostic subgroup, can be further subdivided by the CIMP status. This is a study from the Lind and Lothe groups in collaboration with the clinical research team of Arild Nesbakken.